journal article
LitStream Collection
Railroading at the FDA
2016 Nature Medicine
doi: 10.1038/nm.4234pmid: 27824816
The US Food and Drug Administration approved a muscular-dystrophy drug against the scientific advice of its own staff and advisors. Despite leadership's attempts to downplay the controversy, doubts now surround standards for accelerated approval.